🔗 Share this article

As the US continues making sweeping revisions to its vaccine recommendations, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who rose to prominence by questioning Covid vaccines during the pandemic and has concentrated on potential fatalities following COVID-19 immunization in her short tenure at the FDA.

Scheduled Overhauls to Childhood Vaccine Schedule

Agency leaders had intended to unveil major changes to the pediatric vaccination calendar recently, synchronizing the US with Denmark’s vaccine program, it is understood – a major change that would put the US at odds with many the international standard with little proof for benefit. The announcement has been pushed back until the new year.

Rather than the director of the vaccine center, Høeg is scheduled to address the audience at the event. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to run the center this year.

Consolidating Power at the Agency

Høeg's temporary position could signify a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the agency – and it suggests a renewed priority upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for ending some childhood shot schedules in the US to become more like Denmark, a nation with nationalized medicine and a number of inhabitants about the population of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on immunizations – typically the domain of Dr. Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Background

Høeg has no obvious track record in drug development, oversight or leadership, which has been standard for former leaders of the biologics center. She has served at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for running the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She lacks experience in leading a large organization. She lacks background in industry regulation.”

Former commissioners of CBER would “understand legal statutes and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she lacks the kind of background that previous people who headed CBER have had.”

The drug center has an immense range of responsibilities at the FDA, she emphasized.

“Many people just focuses on the new drug program, but the generic program approves thousands of off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and so forth, and each of these have to be managed,” Dr. Woodcock said. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a significant administrative component to the job, which supervises more than 5,000 employees. “It is a massive management job, if you do it right,” she said.

Agency Reaction and Controversial Programs

When asked about questions about Dr. Høeg's credentials and whether this appointment represents greater collaboration among FDA leaders on immunizations, a press secretary stated that the “inquiries stem from incorrect presumptions”.

“This background is consistent with the functions of her role,” the spokesperson stated, noting the time Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a contentious rapid medication authorization process that apparently worried her predecessors. “How are these medications being picked for this fast-track system? Who is making the choices?” Howard said. “There is a lot of lack of transparency occurring at the FDA right now.”

Overall, he remarked, “the FDA appears to be shifting towards laxer oversight of most medications, except for vaccines.”

Public Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a clearer, if problematic, past, Howard have noted. She released a research paper using non-validated volunteer-provided data to determine the rate of myocarditis following COVID-19 immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Part of her “wish list” for the incoming government encompassed altering guidelines for new vaccines and discontinuing “optional” vaccines, she remarked after the election on a podcast. At the FDA, Dr. Høeg has reportedly suggested barring teenage boys from obtaining Covid vaccines.

“She’s an all-around true believer who starts off with her beliefs and tailors the evidence to accommodate the evidence in a very disingenuous, dishonest manner,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg joined other skeptics, {like|